Telix, Monrol reach agreement on therapeutic isotope supply

2019 11 11 22 17 5854 Arrows Join Partner 400

Telix Pharmaceuticals has signed a global clinical supply agreement with Istanbul-based Eczacıbaşı-Monrol Nuclear Products (Monrol) for the supply of no-carrier-added lutetium-177 (Lu-177), a therapeutic isotope used in Telix's portfolio of molecularly targeted radiation products.

Under the terms of the agreement, Monrol will supply the isotope for clinical and commercial use in support of Telix's development programs. The deal builds on an existing agreement the two firms established in 2019 to support a phase III trial of Telix's TLX250-CDx for PET imaging of renal carcinoma, Telix said.

Page 1 of 436
Next Page